SCHEMBL310048

SCHEMBL310048

COc1ccc(C(=O)Nc2c(F)cccc2F)cc1C(=O)Cc1ccnc(Cl)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 6/20 0.53
PDE4A P27815 2/20 0.47
PDE4B Q07343 2/20 0.47
PDE4C Q08493 2/20 0.47
ALDH1A1 P00352 1/20 0.44
KCNQ3 O43525 1/20 0.42
KCNQ2 O43526 1/20 0.42
POLB P06746 2/20 0.41
GAA P10253 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM4E B2RXH2 1/20 0.41
AURKA O14965 1/20 0.41
RPS6KB1 P23443 1/20 0.41
AURKB Q96GD4 1/20 0.41
HDAC8 Q9BY41 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
PYGL P06737 1/20 0.40
PYGM P11217 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL310100 0.94 PDE4D (0.48) PDE4DPDE4APDE4BPDE4CALDH1A1
SCHEMBL310379 0.84 MEN1 (0.41) PDE4DALDH1A1KCNQ3KCNQ2MEN1
SCHEMBL310313 0.78 PDE4D (0.47) PDE4DPDE4APDE4BPDE4CALDH1A1
SCHEMBL310312 0.78 PDE4D (0.47) PDE4DPDE4APDE4BPDE4CALDH1A1
SCHEMBL2254723 0.77 TRPV1 (0.40) ALDH1A1POLBMEN1KMT2AKDM4E
SCHEMBL29751867 0.76 RAB9A (0.48) ALDH1A1GAAMEN1KMT2AKDM4E
SCHEMBL309542 0.74 RAB9A (0.57) ALDH1A1MEN1KMT2AMAPTNPC1
SCHEMBL24761234 0.74 PDE4D (0.49) PDE4DPOLBMAPTNPC1RAB9A
SCHEMBL13981648 0.72 LMNA (0.49) PDE4DPDE4APDE4BPDE4CALDH1A1
SCHEMBL2254867 0.72 KMT2A (0.41) ALDH1A1POLBMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2162454-B1 IMIDAZOPYRIDINE KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-01-02 EP disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 US disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300242-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 PDE4D 596/4885PDE4A 496/4885PDE4B 551/4885
US-20100216779-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 PDE4D 596/4885PDE4A 496/4885PDE4B 551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.